Gastroparesis Market: Increasing Geriatric Population Accelerating Demand for Gastroparesis Treatment Modalities

The gastroparesis market was valued at US$ 4,338.61 million in 2019 and is projected to reach US$6,025.11 millionby 2027; it is expected to grow at a CAGR of 4.3%from 2020 to 2027.

The gastroparesis market was valued at US$ 4,338.61 million in 2019 and is projected to reach US$6,025.11 millionby 2027; it is expected to grow at a CAGR of 4.3%from 2020 to 2027.

Gastroparesis is a medical condition characterized by the disability of stomach to empty itself of food in the usual way. Damaged nerves such as vagus nerves and muscles associated with gastric motility may also lead to gastroparesis. The condition is commonly observed in diabetic people. Gastroparesis can be classified as diabetic, idiopathic, and post-surgical on the basis of the cause. Apart from these, viral infections, nerve-related diseases, excessive narcotics and several antidepressant consumption, and amyloidosis may also lead to the onset of gastroparesis.

The COVID-19 pandemic has disrupted supply chain of over-the-counter (OTC) and prescription drugs, and this is likely to limit the market growth in the next few quarters. Moreover, the emphasis of health care providers and medical industries on COVID-19 has led to the lowered focus on the diagnosis and treatment for gastroparesis, which is limiting the market growth to a certain extent.

Request for sample Report at: https://www.theinsightpartners.com/sample/TIPRE00008992/

Key Findings from The Gastroparesis Market

On the basis of type, the gastroparesis market is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019, while the diabetic segment is estimated to register the highest CAGR during the forecast period.

The gastroparesis market, based on drug class type, is segmented into prokinetic agents, antiemetic agents, and botulinum toxin injections. The prokinetic agents segment held the largest market share in 2019 and is estimated to register the highest CAGR during 20202027.

On the basis of distribution channel, the gastroparesis market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019, and the market for the same is estimated to grow at the highest CAGR from 2020 to 2027.

EVOKE PHARMA, Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.), Johnson And Johnson Services, Inc., Allergan Plc, NEUROGASTRX, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD, Pfizer Inc., ANI Pharmaceuticals, Inc., Ipca Laboratories Ltd., and Cinrx Pharma, LLC (Cindome Pharma) are among the leading companies operating in the gastroparesis market.

Increasing Geriatric Population Accelerating Demand for Gastroparesis Treatment Modalities

Gastric emptying is associated with the coordination among the motor activity of proximal stomach, distal stomach, and duodenum. These internal organs are controlled by the feedback mechanism from neural signals generated through the interaction between nutrients and small intestine. Aging leads to diminished homeostatic regulations of physiologic functions, along with the slowing of gastric emptying. Moreover, it influences motor and sensory functions. In addition, geriatric population is highly vulnerable to gastroparesis due to factors such as the poor oral medication absorption, inadequate appetite regulation, and postprandial glycemia. According to the 2019 revision of World Population Prospects, 1 in 6 people would be aged more than 65 by 2050, with an increase from 1 in 11 in 2019. Furthermore, according to the same study, one in four people in Europe and North America is projected to be aged over 65 by 2050. Also, the number of people with age more than 80 would reach 426 million by 2050 from 143 million in 2019. Thus, the continuous increase in aging population, coupled with the rise in issues associated with gastric emptying among these populations, drives the gastroparesis market growth.

Gastroparesis Market – by Type

  • Idiopathic
  • Diabetic
  • Post-surgical
  • Others

Gastroparesis Market – by Drug Class Type

  • Prokinetic Agents
  • Botulinum Toxin Injections
  • Antiemetic Agents

Gastroparesis Market – by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Place an Order Now: https://www.theinsightpartners.com/buy/TIPRE00008992/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

Contact Us

Contact Person: Sameer Joshi

Phone: +1-646-491-9876

Email- sales@theinsightpartners